JP7636742B2 - 制御送達性クロマカリムプロドラッグ - Google Patents

制御送達性クロマカリムプロドラッグ Download PDF

Info

Publication number
JP7636742B2
JP7636742B2 JP2022535602A JP2022535602A JP7636742B2 JP 7636742 B2 JP7636742 B2 JP 7636742B2 JP 2022535602 A JP2022535602 A JP 2022535602A JP 2022535602 A JP2022535602 A JP 2022535602A JP 7636742 B2 JP7636742 B2 JP 7636742B2
Authority
JP
Japan
Prior art keywords
formula
compound
pharma
ceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022535602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506776A5 (https=
JP2023506776A (ja
Inventor
トゥレイン エム． トゥー
バーバラ エム． ヴィロストコ
マイケル ピー． フォーシュ
イアン ガーネット
キアラ マサレンティ
Original Assignee
クラリス バイオ インコーポレイテッド
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クラリス バイオ インコーポレイテッド, メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ filed Critical クラリス バイオ インコーポレイテッド
Publication of JP2023506776A publication Critical patent/JP2023506776A/ja
Publication of JP2023506776A5 publication Critical patent/JP2023506776A5/ja
Application granted granted Critical
Publication of JP7636742B2 publication Critical patent/JP7636742B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022535602A 2019-12-12 2020-12-11 制御送達性クロマカリムプロドラッグ Active JP7636742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947342P 2019-12-12 2019-12-12
US62/947,342 2019-12-12
PCT/US2020/064629 WO2021119503A1 (en) 2019-12-12 2020-12-11 Controlled-delivery cromakalim prodrugs

Publications (3)

Publication Number Publication Date
JP2023506776A JP2023506776A (ja) 2023-02-20
JP2023506776A5 JP2023506776A5 (https=) 2023-12-18
JP7636742B2 true JP7636742B2 (ja) 2025-02-27

Family

ID=76330627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535602A Active JP7636742B2 (ja) 2019-12-12 2020-12-11 制御送達性クロマカリムプロドラッグ

Country Status (7)

Country Link
US (1) US12454539B2 (https=)
EP (1) EP4072543A4 (https=)
JP (1) JP7636742B2 (https=)
CN (1) CN115443132A (https=)
AU (1) AU2020403144A1 (https=)
CA (1) CA3159771A1 (https=)
WO (1) WO2021119503A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021215932A1 (en) * 2020-02-07 2022-09-15 Mayo Foundation For Medical Education And Research Improved methods and compositions for cromakalim prodrug therapy
EP4384162A4 (en) * 2021-08-12 2025-06-04 Qlaris Bio, Inc. Compositions and methods for extended-release bromo-kallim therapy
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
CN119970613B (zh) * 2025-02-10 2026-03-03 中国人民解放军总医院 一种埃他卡林微针及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117024A1 (en) 2014-01-31 2015-08-06 Mayo Foundation For Medical Education And Research Novel therapeutics for the treatment of glaucoma

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
US3361816A (en) 1961-02-20 1968-01-02 Schering Corp Novel therapeutic compounds and processes for their manufacture
US3251837A (en) 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US4200640A (en) 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
IE52935B1 (en) 1981-04-15 1988-04-13 Leo Pharm Prod Ltd Pharmaceutical preparation
GB8308062D0 (en) 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
US4616012A (en) 1983-11-25 1986-10-07 Schering Corporation Carboxyalkyl dipeptides as antiglaucoma agents
US4634698A (en) 1984-09-24 1987-01-06 Schering Corporation Antiglaucoma agents
GB8730051D0 (en) 1987-12-23 1988-02-03 Beecham Group Plc Novel compounds
AU628331B2 (en) 1988-05-06 1992-09-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
WO1989010757A1 (en) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
GB8822743D0 (en) 1988-09-28 1988-11-02 Beecham Group Plc Novel compounds
GB8927980D0 (en) 1989-12-11 1990-02-14 Beecham Group Plc Pharmaceuticals
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5328830A (en) 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5965620A (en) 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US6242443B1 (en) 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
FR2767692B1 (fr) 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
CN101327325A (zh) 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
FR2852245B1 (fr) 2003-03-11 2006-08-11 Utilisation du diazoxide dans le traitement de l'ischemie retinienne
ES2342090T3 (es) 2004-08-25 2010-07-01 Essentialis, Inc. Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos.
GB0702972D0 (en) * 2007-02-15 2007-03-28 Cambridge Entpr Ltd Induction of autography
JP5681723B2 (ja) 2009-11-20 2015-03-11 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
JP2011136923A (ja) 2009-12-28 2011-07-14 Lion Corp ソフトコンタクトレンズ用点眼剤
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
DK2838533T3 (da) 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
AU2015296640B2 (en) * 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2018047175A1 (en) 2016-09-08 2018-03-15 Regenera Pharma Ltd. Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
AU2021215932A1 (en) 2020-02-07 2022-09-15 Mayo Foundation For Medical Education And Research Improved methods and compositions for cromakalim prodrug therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117024A1 (en) 2014-01-31 2015-08-06 Mayo Foundation For Medical Education And Research Novel therapeutics for the treatment of glaucoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Uttio ROY CHOWDHURY et al.，Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity，Journal of Medicinal Chemistry，2016年07月01日，Vol. 59，No. 13，p.6221-6231
Uttio ROY CHOWDHURY et al.，Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents，Investigative Opthalmology & Visual Science，2017年11月，Vol. 58，No. 13，p.5731-5742

Also Published As

Publication number Publication date
US12454539B2 (en) 2025-10-28
EP4072543A4 (en) 2024-02-07
CN115443132A (zh) 2022-12-06
US20220324890A1 (en) 2022-10-13
WO2021119503A1 (en) 2021-06-17
CA3159771A1 (en) 2021-06-17
JP2023506776A (ja) 2023-02-20
EP4072543A1 (en) 2022-10-19
AU2020403144A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
JP7636742B2 (ja) 制御送達性クロマカリムプロドラッグ
CN109528721B (zh) 联合治疗
US20220387457A1 (en) Methods and compositions for cromakalim prodrug therapy
JP2019038825A (ja) 治療用化合物の結晶形態及びその使用
EA016227B1 (ru) Способ лечения офтальмологических неоваскулярных расстройств
CA2581126A1 (en) Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20200308162A1 (en) Drugs and compositions for ocular delivery
IL126836A (en) Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases
JP2024532015A (ja) 徐放性クロマカリム療法用の組成物及び方法
CN113661170A (zh) 地塞米松二聚体的结晶形式及其用途
JP5875585B2 (ja) 緑内障および高眼圧症の処置のためのアデノシンａ１アゴニスト
JP2019038824A (ja) 治療用化合物の結晶形態及びその使用
ES2717481T3 (es) Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos
JP2014193854A (ja) テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤
HK40004468A (en) Combination therapy
HK40004468B (zh) 联合治疗
EP3170500A1 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye
AU5259701A (en) Ocular tension depressor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250204

R150 Certificate of patent or registration of utility model

Ref document number: 7636742

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150